Masking requirement continues in California health care settings.
See the latest
As of Jan. 1, 2019, a prescriber must offer to a patient a prescription for naloxone hydrochloride or other FDA-approved drug for the complete or partial reversal of opioid depression when one or more of the following conditions are present:
Additionally, a prescriber must provide education to a patient, or the patient’s guardian if patient is a minor, receiving a prescription per the above circumstance on overdose prevention and the use of naloxone hydrochloride or other FDA-approved drug for the complete or partial reversal of opioid depression. AB 2760